Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Inclusion Criteria: 1. ≥18 years 2. Written informed consent 3. Patients with histologically or cytologically documented chemotherapy-naïve locally advanced unresectable or metastatic ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC, gastric cancer/GEJ, PDAC and ESCC. 4. ECOG performance status of 0 or 1 5. Patients must be considered suitable candidates for, and able to receive, first line chemotherapy for metastatic disease 6. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline 7. No prior exposure to immune-mediated therapy 8. Adequate organ and marrow function as defined below Exclusion Criteria: 1. Receipt of any investigational anticancer therapy within 28 days or 5 halflives, whichever is longer, prior to the first dose of study treatment 2. Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment 3. Any unresolved Grade ≥2 toxicity from previous anticancer therapy 4. Active or prior documented autoimmune or inflammatory disorders 5. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from study drugs, or compromise the ability of the patient to give written informed consent 6. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms 20. Active tuberculosis 7. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)